Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

STROBE-based methodology for detection of adverse events across multiple communities.

Sordo M, Colecchi J, Dubey A, Gainer V, Murphy SN.

AMIA Annu Symp Proc. 2008 Nov 6:1144.

PMID:
18998965
2.

EIDOS: a mechanistic classification of adverse drug effects.

Ferner RE, Aronson JK.

Drug Saf. 2010 Jan 1;33(1):15-23. doi: 10.2165/11318910-000000000-00000.

PMID:
20000863
3.

Improving postapproval drug safety surveillance: getting better information sooner.

Hennessy S, Strom BL.

Annu Rev Pharmacol Toxicol. 2015;55:75-87. doi: 10.1146/annurev-pharmtox-011613-135955. Review.

4.

Encouraging spontaneous reporting of adverse effects.

[No authors listed]

Prescrire Int. 2015 Feb;24(157):53.

PMID:
25802925
5.

Towards on-line ADR detection: an innovative data cube-based approach.

Lin WY, Du JW.

Stud Health Technol Inform. 2013;192:1218.

PMID:
23920992
6.

Editorial: Communicating vaccine safety - the Vienna Vaccine Safety Initiative.

Rath B.

Curr Drug Saf. 2015;10(1):3-4. No abstract available.

PMID:
25859667
7.

On pharmaceutical risk minimization.

Callréus T.

Drug Saf. 2008;31(9):737-42.

PMID:
18707188
8.

Natural language processing to identify adverse drug events.

Gysbers M, Reichley R, Kilbridge PM, Noirot L, Nagarajan R, Dunagan WC, Bailey TC.

AMIA Annu Symp Proc. 2008 Nov 6:961.

PMID:
18999130
9.
10.

Reporting adverse experiences related to drugs: an ontology-based tool to help the citizens.

De Lazzari C, Battaglia M, Pisanelli DM.

AMIA Annu Symp Proc. 2008 Nov 6:923.

PMID:
18998793
11.

Hospital-based adverse drug reaction bulletin : an Indian experience.

Jose J, Rao PG, Jimmy B.

Drug Saf. 2007;30(5):457-9. No abstract available.

PMID:
17472423
12.

Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads.

Castel JM, Figueras A, Pedrós C, Laporte JR, Capellà D.

Drug Saf. 2003;26(14):1049-55.

PMID:
14583065
13.

Evolving paradigms in pharmacovigilance.

Brewster W, Gibbs T, Lacroix K, Murray A, Tydeman M, Almenoff J.

Curr Drug Saf. 2006 May;1(2):127-34.

PMID:
18690923
14.

Cadec: A corpus of adverse drug event annotations.

Karimi S, Metke-Jimenez A, Kemp M, Wang C.

J Biomed Inform. 2015 Jun;55:73-81. doi: 10.1016/j.jbi.2015.03.010.

15.
16.

Network influences on dissemination of evidence-based guidelines in state tobacco control programs.

Luke DA, Wald LM, Carothers BJ, Bach LE, Harris JK.

Health Educ Behav. 2013 Oct;40(1 Suppl):33S-42S. doi: 10.1177/1090198113492760.

PMID:
24084398
17.

Measuring the preventability of adverse drug reactions in France: A 2015 overview.

Olivier-Abbal P.

Therapie. 2016 Apr;71(2):195-202. doi: 10.1016/j.therap.2016.02.014. English, French.

PMID:
27080838
18.

Community-wide implementation of health information technology: the Massachusetts eHealth Collaborative experience.

Goroll AH, Simon SR, Tripathi M, Ascenzo C, Bates DW.

J Am Med Inform Assoc. 2009 Jan-Feb;16(1):132-9. doi: 10.1197/jamia.M2899.

19.

Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.

Ferranti J, Horvath MM, Cozart H, Whitehurst J, Eckstrand J.

Pediatrics. 2008 May;121(5):e1201-7. doi: 10.1542/peds.2007-2609.

PMID:
18450863
20.

CNODES: the Canadian Network for Observational Drug Effect Studies.

Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P, Hemmelgarn B, Lelorier J, Levy A, Martens PJ, Paterson JM, Platt RW, Sketris I, Teare G; Canadian Network for Observational Drug Effect Studies (CNODES)..

Open Med. 2012 Oct 30;6(4):e134-40.

Items per page

Supplemental Content

Support Center